Navigation Links
Longer Drug Regimen Still Best Against Breast Cancer
Date:6/2/2010

Giving meds sequentially, not concurrently, gives survival edge for those with early stage disease, study finds

WEDNESDAY, June 2 (HealthDay News) -- For patients with early stage breast cancer, taking chemotherapy drugs sequentially over six months helps improve their survival compared to taking them at the same time over a shorter three-month span, a new study found.

The new findings will probably come as a relief to doctors, most of whom already follow the sequential protocol, said Dr. Bhuvaneswari Ramaswamy, a breast oncologist with the Ohio State University Comprehensive Cancer Center--Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus.

But the "most exciting and surprising finding," said study lead author Dr. Sandra M. Swain, was that younger women who went into early menopause because of their chemotherapy -- in other words, those who stopped having periods -- were more likely to live longer.

"That's something that's not been reported," added Swain, who is medical director of the Washington Cancer Institute, Washington Hospital Center in Washington, D.C.

And this was true irrespective of whether the women's cancers were estrogen-receptor positive (meaning estrogen furthers their growth) or not.

In the study, reported in the June 3 issue of the New England Journal of Medicine, the authors tracked outcomes for almost 5,400 women with early stage breast cancer that had spread to at least one lymph node.

The patients were randomly divided into one of three treatment groups: the sequential group, which involved three drugs (doxorubicin, cyclophosphamide and docetaxel) taken in sequence over six months; or one of two "concurrent" groups, where women received either two or three of these medications concurrently for three months.

After eight years of follow-up, 83 percent of patients in the sequential group were still alive compared to 79 percent of those in the concurrent groups, the authors report.

Disease-free survival was also better in the sequential group, leading to the conclusion that a longer course of treatment remains better than a shorter course, the study said.

However, an accompanying editorial in the journal pointed out that the side effects associated with the longer program might not be worth the small survival advantage for many women.

As to the issue of amenorrhea (cessation of menstrual cycles) also improving survival, Swain said, this "really generated a new hypothesis that connects cessation of menses with survival."

No periods mean less estrogen is circulating in the body and estrogen is known to fuel certain types of cancers. But that isn't a likely explanation in this study, given that amenorrhea also resulted in longer survival even in women whose tumors were estrogen-receptor (ER) negative -- that is, their cancers don't respond to estrogen.

"This [study] gives us a hint that women who stop having their periods -- even in the patients who are not ER positive -- may have a survival advantage," said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La.

However, given that so much remains unknown, the message to women is not that suppressing ovarian function is a way to reduce their risk of breast cancer, said another study author, Dr. Charles E. Geyer Jr., director of medical affairs of the National Surgical Adjuvant Breast and Bowel Project (which conducted the trial) and vice chair of human oncology at Allegheny General Hospital in Pittsburgh.

More information

To learn more about breast cancer, visit the U.S. National Cancer Institute.



SOURCES: Bhuvaneswari Ramaswamy, M.D., breast oncologist, Ohio State University Comprehensive Cancer Center--Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus; Sandra M. Swain, M.D., medical director, Washington Cancer Institute, Washington Hospital Center, Washington D.C.; Charles E. Geyer Jr., M.D., director of medical affairs, NSABP and vice chair of human oncology, Allegheny General Hospital, Pittsburgh; Jay Brooks, M.D., chairman of hematology/oncology, Ochsner Health System, Baton Rouge, La.; June 3, 2010, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Using Nicotine Patch Longer Boosts Efforts to Quit
2. Sedation Linked to Longer Stay in ICU
3. Zambian study finds longer breastfeeding best for HIV-infected mothers
4. Pet Health Insurance Grows as Pets Live Longer and Healthier Lives
5. Marijuana Use No Longer Dropping Among U.S. Teens
6. Looking Younger Than Your Age May Mean Longer Life
7. Military children face more emotional challenges as parental deployments grow longer, study finds
8. Glaucoma Drugs May Play Role in Longer Life
9. Biological clock could be a key to better health, longer life
10. Big Smiles, Longer Lives?
11. Perhaps a longer lifespan, certainly a longer health span
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... , the only authorized OSHA Training Institute Education Center headquartered in Northern California, ... their workers from extreme heat at their worksites. Employers with workers exposed ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... "FCPX editors ... customizable inside of Final Cut Pro X," said Christina Austin - CEO of Pixel ... style. Final Cut Pro X users can now reveal the media of ...
(Date:6/27/2016)... ... , ... TherapySites, the leading website and online ... Counseling Association. This new relationship allows TherapySites to continue to extend their ... benefits and promotional offers. , "TCA is extremely excited about this new partnership, ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... payment industry today announced its strategic partnership with Connance, a healthcare industry ... The two companies’ proven, proprietary technology combine to provide health systems, hospitals ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... transport experience for the millions of people who require these medical transport services ... industry through the use of technology. Now, SmartEMS has put forth an industry-changing ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology: